ReviewFrontiers in endocrinology2026
Risk stratification of MASLD/MASH in type 2 diabetes: a pragmatic endocrinology outpatient pathway.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with type 2 diabetes mellitus (T2DM) have a high burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), but liver fibrosis risk is still not assessed consistently in routine diabetes care. Recent guidelines now support active fibrosis risk stratification in metabolically high-risk populations, yet many endocrinology clinics lack a workable pathway for implementation. This narrative review proposes a risk-adapted outpatient pathway for MASLD/MASH assessment in patients with T2DM. The pathway starts with automated fibrosis-4 index (FIB-4) calculation using routine laboratory data, followed by second-line non-invasive assessment with FibroScan controlled attenuation parameter/liver stiffness measurement or enhanced liver fibrosis testing in patients with indeterminate or high-risk results. Patients at high risk should be referred for hepatology evaluation, with magnetic resonance imaging-proton density fat fraction or magnetic resonance elastography reserved for selected cases in which quantitative assessment or further staging would alter management. The review also addresses implementation barriers, appropriate use of non-invasive tests, treatment strategies with metabolic and liver-related evidence, and validation indicators for real-world assessment. By linking screening, referral, intervention, follow-up and quality control, the proposed pathway aims to move MASLD/MASH care in T2DM from incidental recognition toward structured, measurable and multidisciplinary risk management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.